Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 6-8, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Petty, E. M.
Right arrow Articles by Killeen, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petty, E. M.
Right arrow Articles by Killeen, A. A.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Laboratory Management
Right arrow Evidence Based Laboratory Medicine and Test Utilization
(Clinical Chemistry. 1997;43:6-8.)
© 1997 American Association for Clinical Chemistry, Inc.

Editorials

BRCA1 Mutation Testing: Controversies and Challenges

Elizabeth M. Petty1,a and Anthony A. Killeen2

1 Departments of Medicine and
2 Pathology University of Michigan 1301 Catherine St. Ann Arbor, MI 48109-0602
a Author for correspondence

Breast cancer is a leading cause of significant morbidity and mortality for women. Methods to reliably detect the earliest stages of breast cancer have been widely sought because the success of breast cancer treatment is influenced by how early a malignancy is diagnosed. Current methods for early detection rely on either physical examination to palpate a tumor or radiography. The development of genetic tests that enable accurate risk assessment for individuals in high-risk families has been predicted to have substantial medical benefits. Significant and unprecedented media fanfare informed both medical professionals and the general public about exciting new discoveries in breast cancer genetics, namely, identification of two critically important breast cancer genes BRCA1 and BRCA2, helping to create an immediate demand for clinical tests for these genes. The identification of genetic alterations underlying the development of breast cancer has ushered in an exciting and challenging new era in oncology, genetics, and molecular diagnostics.

DNA diagnostic tests for breast cancer genes, including BRCA1, BRCA2, and TP53 (which causes breast cancer in the context of the Li–Fraumeni cancer predisposition syndrome), are currently available in most cases only for individuals who have clear family histories of one of the hereditary breast cancer syndromes. Presymptomatic DNA-based assessment for breast cancer risk has had only limited use in clinical practice to date. In cases of autosomal dominant breast cancer (~5% of all breast cancers), identification of the specific BRCA disease-causing mutation has enabled more-accurate risk-modification counseling for first-degree relatives and facilitated susceptibility testing for family members. Presymptomatic identification of a germ-line BRCA mutation provides individuals with specific, if not yet well studied, options for preventive medical management. For example, initial studies indicate that women who have inherited a mutant BRCA1 allele from an affected mother have a markedly increased risk of developing . . . [Full Text of this Article]


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.